These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7883968)

  • 21. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-Péotti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
    Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanisms for resistance and cross-resistance patterns of cisplatin-resistant tumor lines].
    Tashiro T
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):509-14. PubMed ID: 2321979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.
    Jamshidipour R; Pinho EB; Hom DK; Howell SB
    Cancer Chemother Pharmacol; 1994; 34(6):484-90. PubMed ID: 7923559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.
    Andrews PA; Murphy MP; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(2):149-54. PubMed ID: 3568272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells.
    Jekunen AP; Hom DK; Alcaraz JE; Eastman A; Howell SB
    Cancer Res; 1994 May; 54(10):2680-7. PubMed ID: 8168097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
    Chau Q; Stewart DJ
    Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer.
    Wang B; Yu W; Guo J; Jiang X; Lu W; Liu M; Pang X
    J Pharmacol Exp Ther; 2015 Jan; 352(1):129-38. PubMed ID: 25352499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
    Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY
    Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
    Holzer AK; Katano K; Klomp LW; Howell SB
    Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of an aquaglyceroporin AQP1 null mutant in Leishmania major.
    Plourde M; Ubeda JM; Mandal G; Monte-Neto RL; Mukhopadhyay R; Ouellette M
    Mol Biochem Parasitol; 2015 Jun; 201(2):108-11. PubMed ID: 26222914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells.
    Andrews PA; Murphy MP; Howell SB
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):619-25. PubMed ID: 2714338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells.
    Lin X; Okuda T; Trang J; Howell SB
    Mol Pharmacol; 2006 May; 69(5):1748-54. PubMed ID: 16495473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.